# Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions

> **NCT00372710** · PHASE3 · TERMINATED · sponsor: **Novartis** · enrollment: 30 (—)

## Conditions studied

- Breast Cancer With Bone Metastasis

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00372710
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (—)
- **Last updated:** 2009-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372710, "Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00372710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*